N. Geller

N. Geller, E. Altmaier, S. Davies, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Relation Between Clinical, Angiographic and Ischemic Findings at Baseline and Ischemia-Related Adverse Outcomes at 1 Year in the Asymptomatic Cardiac Ischemia Pilot Study

N. Geller, P. Stone, G. Knatterud, 2016 .

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone‐refractory prostatic cancer treated with single‐agent chemotherapy

N. Geller, H. Scher, Z. Li, 1992, Cancer.

Coping with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

J. L. Rosenberger, Kelly Van Lancker, N. Geller, 2022, Statistics in Biopharmaceutical Research.

A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)‐Fc fusion protein in patients with myelodysplastic syndrome

N. Geller, N. Young, J. Maciejewski, 2002, British journal of haematology.

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

N. Geller, N. Bander, H. Scher, 1989, Cancer.

Carboplatin, etoposide, and bleomycin for patients with poor‐risk germ cell tumors

N. Geller, R. Motzer, H. Scher, 1990, Cancer.

Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification

E. Dmitrovsky, M. Ladanyi, N. Geller, 1990, Genes, chromosomes & cancer.

The role of ifosfamide plus cisplatin‐based chemotherapy as salvage therapy for patients with refractory germ cell tumors

E. Dmitrovsky, N. Geller, P. Russo, 1990, Cancer.

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

N. Geller, J. Auman, H. Scher, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.

N. Geller, M. Bains, N. Martini, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Behavioral and pharmacologic interventions: the Raynaud's Treatment Study.

N. Geller, P. Kaufmann, L. Bielory, 1999, Controlled clinical trials.

Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.

R. Wittes, N. Geller, G. Petroni, 1985, Cancer research.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

E. Leifer, N. Geller, H. Deeg, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implementation of the Group Sequential Methodology in a Randomized Trial in Metastatic Colorectal Carcinoma

N. Geller, N. Kemeny, B. Reichman, 1988, American journal of clinical oncology.

High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial

N. Geller, N. Young, A. Barrett, 2000, The Lancet.

Gallium nitrate in prostatic cancer: evaluation of antitumor activity and effects on bone turnover.

N. Geller, H. Scher, D. Dershaw, 1987, Cancer treatment reports.

Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial

N. Geller, R. Childs, G. Calandra, 2016, Haematologica.

Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy.

N. Geller, S. Piechnik, S. Neubauer, 2015, American heart journal.

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

E. Leifer, N. Geller, H. Deeg, 2015 .

Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.

N. Geller, S. Piechnik, S. Neubauer, 2019, Journal of the American College of Cardiology.

Randomized Study of Intrahepatic vs Systemic Infusion of Fluorodeoxyuridine in Patients with Liver Metastases from Colorectal Carcinoma (Preliminary Results)

N. Geller, N. Kemeny, G. Petroni, 1984 .

Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993--the perspective of NIH clinical trialists.

N. Geller, D. Gordon, L. Freedman, 1995, Controlled clinical trials.

Commentary on ‘Redesign of trials under different enrolment mixes’ by Curtis L. Meinert

N. Geller, 1999 .

Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.

N. Geller, W. Whitmore, H. Oettgen, 1985, Cancer treatment reports.

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.

N L Geller, S A Forman, B. Hoogwerf, 1999, Circulation.

Delayed progression of atherosclerosis in coronary bypass grafts is similar in women compared to men following aggressive cholesterol lowering despite more frequent risk factors: post CABG trial

B. Hoogwerf, C. White, M. Domanski, 1998 .

Serum tumor markers and patient allocation to good‐risk and poor‐risk clinical trials in patients with germ cell tumors

N. Geller, D. Bajorin, G. Bosl, 1991, Cancer.

Nephrotic syndrome: an under‐recognised immune‐mediated complication of non‐myeloablative allogeneic haematopoietic cell transplantation

N. Geller, R. Srinivasan, Y. Takahashi, 2005, British journal of haematology.

Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study

N. Geller, A. Krishnan, P. Hari, 2019, Biology of Blood and Marrow Transplantation.

Two‐drug therapy in patients with metastatic germ cell tumors

N. Geller, D. Bajorin, G. Bosl, 1991, Cancer.

Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF

J. P. McCoy, N. Geller, J. Joo, 2013, Journal of Immunology.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce

N. Geller, P. Hari, D. Porter, 2019, The Lancet. Haematology.

Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience.

N. Geller, G. Bosl, W. Whitmore, 1983, The American journal of medicine.

Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.

N. Geller, H. Scher, G. Bosl, 1983, Cancer research.

Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis

N. Geller, G. Bosl, W. Whitmore, 1983, Cancer.

Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection.

N. Geller, R. Motzer, H. Scher, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.

N L Geller, S J Pocock, S. Pocock, 1987, Biometrics.

Statistics: An All-Encompassing Discipline

Nancy L. Geller, N. Geller, 2011 .

Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.

N. Geller, R. Srinivasan, A. Barrett, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation

N. Geller, R. Srinivasan, N. Young, 2006, British journal of haematology.

Carcinoma of major salivary glands. Recent trends.

R. Spiro, E. Strong, N. Geller, 1989, Archives of Otolaryngology - Head and Neck Surgery.

Systemic absorption of a leucovorin mouth wash: a pharmacologic study.

N. Geller, N. Kemeny, J. Fiore, 1987, Cancer investigation.

Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.

N. Geller, G. Bosl, J. Nisselbaum, 1990, Cancer research.

Serum Tumor Markers in Patients With Metastatic Germ Cell Tumors of the Testis

N. Geller, W. Whitmore, C. Cirrincione, 1984 .

Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features

N. Geller, G. Bosl, G. Toner, 1991, Cancer.

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.

N. Geller, D. Bajorin, G. Bosl, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isochromosome of Chromosome 12: Clinically Useful Marker for Male Germ Cell Tumors

E. Dmitrovsky, N. Geller, V. Reuter, 1989 .

Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors.

E. Dmitrovsky, N. Geller, V. Reuter, 1989, Journal of the National Cancer Institute.

Lipid-associated sialic acid test for the detection of human cancer.

N. Geller, C. Stock, Y. Hirshaut, 1982, Cancer research.

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.

N. Geller, J. Auman, G. Bosl, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage chemotherapy for patients with germ cell tumors. The memorial sloan‐kettering cancer center experience (1979–1989)

N. Geller, R. Motzer, P. Russo, 1991, Cancer.

Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.

N. Geller, D. Bajorin, G. Bosl, 1988, Seminars in oncology.

Stage migration and the increasing proportion of complete responders in patients with advanced germ cell tumors.

N. Geller, G. Bosl, E. Chan, 1988, Cancer research.

Prognostic factors in advanced ovarian carcinoma.

N. Geller, P. Saigo, G. Petroni, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.

N. Geller, R. Motzer, M. Mazumdar, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of chromosome 12 abnormalities in male germ cell cancers.

E. Dmitrovsky, N. Geller, V. Reuter, 1991, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.

N. Geller, G. Bosl, H. Herr, 1991, European urology.

Advanced Seminoma: The Role of Chemotherapy and Adjunctive Surgery

N. Geller, R. Motzer, W. Fair, 1988, Annals of Internal Medicine.

Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study

M. Domanski, N. Geller, Y. Rosenberg, 2004, Circulation.

Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

N. Geller, N. Kemeny, J. Daly, 1987, Annals of internal medicine.

Clinical Evaluation of Anticancer Treatments: Phase II Clinical Trials

N. Geller, H. Scher, F. Muggia, 1987 .

Endotoxin‐induced in vitro release of interleukin‐1 by cancer patients' monocytes: Relation to stage of disease

N. Geller, W. Enker, H. Oettgen, 1983, International journal of cancer.

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

N. Geller, A. Krishnan, P. Hari, 2011, The Lancet. Oncology.

Adenocarcinoma of the esophagus and gastroesophageal junction. Prognostic factors and results of therapy

N. Geller, P. McCormack, M. Bains, 1985, Cancer.

On the design and analysis of randomized clinical trials with multiple endpoints.

D I Tang, N L Geller, S J Pocock, 1993, Biometrics.

The analysis of multiple endpoints in clinical trials.

N L Geller, S J Pocock, A A Tsiatis, 1987, Biometrics.

Monitoring multi-armed trials.

D A Follmann, N L Geller, M A Proschan, 1994, Statistics in medicine.

Neural modulation for hypertension and heart failure.

S. Pocock, N. Geller, F. Zannad, 2016, International journal of cardiology.

Advances in Clinical Trial Biostatistics

N. Geller, 2003 .

Anginal status and prediction of cardiac events in patients enrolled in the asymptomatic cardiac ischemia pilot (ACIP) study. ACIP investigators.

N. Geller, G. Knatterud, C. Pepine, 1997, The American journal of cardiology.

Ischemia during ambulatory monitoring as a prognostic indicator in patients with stable coronary artery disease.

N. Geller, A. Quyyumi, D. Mulcahy, 1997, JAMA.

After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer.

E. Feuer, N. Geller, G. Bosl, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

N. Geller, H. Scher, C. Sternberg, 1991, Cancer.

Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors

N. Geller, G. Bosl, Eva Y. W. Chan, 1989, Cancer.

Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer.

N. Geller, H. Scher, G. Bosl, 1988, Cancer research.

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.

N. Geller, G. Petroni, E. Casper, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pancreaticoduodenectomy for Benign Disease

N. Geller, G. T. Shires, P. Dineen, 1983, Annals of surgery.

Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival

P. Nowell, N. Geller, E. Besa, 1982, Cancer.

Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria.

N. Geller, N. Young, P. Scheinberg, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors.

N. Geller, W. Linehan, R. Srinivasan, 2004, Blood.

Meta-analysis of clinical trials: a consumer's guide.

N. Geller, M. Proschan, 1996, Journal of biopharmaceutical statistics.

Rapid donor T‐cell engraftment increases the risk of chronic graft‐versus‐host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes

N. Geller, N. Young, D. Stroncek, 2013, American journal of hematology.

Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).

N. Geller, A. Krishnan, P. Hari, 2020 .

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

N. Geller, A. Krishnan, R. Vij, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Umbilical cord blood transplantation in pediatric patients: Results of the prospective, multi-institutional Cord Blood Transplantation Study (COBLT)

N. Geller, J. Wagner, E. Guinan, 2006 .

Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

N. Geller, H. Hedlin, R. Srinivasan, 2007 .

Surgical ablation of atrial fibrillation during mitral-valve surgery.

N. Geller, M. Mack, M. Acker, 2015, The New England journal of medicine.

Biomarker-guided therapies in heart failure: a forum for unified strategies.

I. Piña, C. O'connor, A. Mebazaa, 2013, Journal of cardiac failure.

Treatment for Mild Chronic Hypertension during Pregnancy.

S. Oparil, N. Geller, G. Saade, 2022, The New England journal of medicine.

Designing comparative effectiveness trials of surgical ablation for atrial fibrillation: experience of the Cardiothoracic Surgical Trials Network.

Denis Bouchard, Eugene H Blackstone, Nancy L Geller, 2011, The Journal of thoracic and cardiovascular surgery.

Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

B. Gersh, M. Domanski, N. Geller, 2005, American heart journal.

Design of phase I and II clinical trials in cancer: a statistician's view.

N L Geller, N. Geller, 1984, Cancer investigation.

Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR.

N. Geller, S. Piechnik, C. Kramer, 2021, JACC. Clinical electrophysiology.

Detecting Acute Coronary Syndrome in the Emergency Department With Cardiac Magnetic Resonance Imaging

Anthony H. Aletras, Andrew E. Arai, Robert S. Balaban, 2003, Circulation.

Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study.

N. Geller, P. Stone, B. Chaitman, 1994, Journal of the American College of Cardiology.

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.

R. Califf, Jeffrey L. Anderson, N. Geller, 2013, American heart journal.

Both Light Intensity and Moderate‐to‐Vigorous Physical Activity Measured by Accelerometry Are Favorably Associated With Cardiometabolic Risk Factors in Older Women: The Objective Physical Activity and Cardiovascular Health (OPACH) Study

J. Manson, A. LaCroix, C. Kooperberg, 2017, Journal of the American Heart Association.

Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome

N. Geller, S. Adams, D. Stroncek, 2021, British journal of haematology.

Rare loss of function variants in candidate genes and risk of colorectal cancer

Taylor J. Maxwell, Jennifer G. Robinson, Andrew J. Sanford, 2018, Human Genetics.

Time course analysis of gene expression identifies multiple genes with differential expression in patients with in-stent restenosis

N. Geller, A. Helgadóttir, G. Thorgeirsson, 2011, BMC Medical Genomics.

Prevention of graft versus host disease with Hematopoietic CellTransplantation with Reduced Intensity Conditioning—a comparison of threeprophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide,tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versustacrolimus/me

N. Geller, P. Hari, M. Pasquini, 2019 .

Management practices and major infections after cardiac surgery.

N. Geller, M. Acker, A. Moskowitz, 2014, Journal of the American College of Cardiology.

Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

N. Geller, W. Wood, H. Jim, 2014 .

Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.

N. Geller, W. Wood, H. Jim, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II trial of mitoguazone in patients with advanced head and neck cancer.

R. Wittes, N. Geller, S. Thongprasert, 1984, Cancer treatment reports.

Use of biological assignment in hematopoietic stem cell transplantation clinical trials

E. Leifer, N. Geller, B. Logan, 2008, Clinical trials.

Non-myeloablative allogeneic stem cell transplantation (NST) for metastatic melanoma: nondurable chemotherapy responses without clinically meaningful graft-vs-tumor (GVT) effects.

E. Leifer, N. Geller, R. Srinivasan, 2002 .

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

N. Geller, M. Perales, H. Heslop, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of 4'-deoxydoxorubicin in patients with advanced breast cancer.

N. Geller, R. Winn, E. Casper, 1985, Cancer treatment reports.

Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Results of the BMT CTN 1301 Progress II Trial

N. Geller, M. Perales, H. Heslop, 2021 .

Evaluation of Three Different Cyclosporine-Based Graft Versus Host Disease (GVHD) Prophylaxis Regimens Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST).

N. Geller, R. Srinivasan, R. Childs, 2004 .

Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.

N. Geller, A. Krishnan, P. Hari, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers

N. Geller, J. Tisdale, R. Childs, 2011, British journal of haematology.

Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100.

N. Geller, R. Childs, A. Lundqvist, 2007 .

Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition.

N. Geller, J. Cleland, B. Pitt, 2008, European heart journal.

Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure.

D. M. Barr, D. F. Hughes, R. Collins, 1996, Controlled clinical trials.

Factors Associated With New‐Onset Depression Following Ischemic Stroke: The Women's Health Initiative

J. Manson, A. LaCroix, C. Kooperberg, 2017, Journal of the American Heart Association.

Cooperative Heart Disease Trials Sponsored by the National Heart, Lung, and Blood Institute (NHLBI)

N. Geller, M. Waclawiw, L. Friedman, 2016 .

Cooperative Heart Disease Trials

N. Geller, L. Friedman, 2005 .

Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis.

K. Bailey, N. Geller, Y. Rosenberg, 2021, JACC. Cardiovascular interventions.

E ffects of Aggressive Cholesterol Lowering and Low-Dose Anticoagulation on Clinical and Angiographic Outcomes in Patients With Diabetes The Post Coronary Artery Bypass Graft Tr i a l

B. Hoogwerf, C. White, M. Domanski, 1999 .

Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study

C. Lewis, N. Geller, C. Furberg, 2012, Clinical trials.

Testing association for markers on the X chromosome

Gang Zheng, Jungnam Joo, Nancy L Geller, 2007, Genetic epidemiology.

Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition.

M. Pfeffer, M. Domanski, E. Braunwald, 1998, The American journal of cardiology.

Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators.

N L Geller, A D Goldberg, S A Forman, 1995, Journal of the American College of Cardiology.

Charting a roadmap for heart failure biomarker studies.

M. Pencina, N. Geller, J. Cleland, 2014, JACC. Heart failure.

Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the Asymptomatic Cardiac Ischemia Pilot [ACIP] Study).

N. Geller, P. Stone, J. Hill, 1996, The American journal of cardiology.

Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial

Jeffrey L. Anderson, N. Geller, Y. Rosenberg, 2010, Trials.

Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry

K. Bailey, J. Olgin, M. Pletcher, 2020, American Heart Journal.

Patient‐reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)

N. Geller, W. Wood, H. Jim, 2016, Cancer.

Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials.

M. Pfeffer, M. Domanski, N. Geller, 1999, Journal of the American College of Cardiology.

Relation of patient characteristics to cardiac ischemia during daily life activity (an Asymptomatic Cardiac Ischemia Pilot Data Bank Study).

N. Geller, P. Stone, J. Hill, 1996, The American journal of cardiology.

Pancreaticoduodenectomy: A 40‐Year Experience

N. Geller, G. T. Shires, P. Dineen, 1982, Annals of surgery.

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

N. Geller, N. Munshi, M. Pasquini, 2021, Blood.

Mitral-valve repair versus replacement for severe ischemic mitral regurgitation.

Timothy J Gardner, Francois Dagenais, Emilia Bagiella, 2014, The New England journal of medicine.

Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation.

Francois Dagenais, Emilia Bagiella, Nancy L Geller, 2016, The New England journal of medicine.

Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes

W. Cushman, N. Geller, J. Bigger, 2016, Diabetes Care.

Monitoring pairwise comparisons in multi-armed clinical trials.

D A Follmann, N L Geller, M A Proschan, 1994, Biometrics.

Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.

N L Geller, B. Hoogwerf, C. White, 2000, Journal of the American College of Cardiology.

Smart Technology in Lung Disease Clinical Trials.

Xin Tian, Nancy L Geller, N. Geller, 2016, Chest.

An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH).

N. Geller, F. Barton, M. Waclawiw, 1997, Controlled clinical trials.

testing treatment efficacy in clinical trials with repeated binary measurements and missing observations

N. Geller, D. Follmann, Margaret C. Wu, 1994 .

Interpreting tests for efficacy in clinical trials with multiple endpoints.

N. Geller, P. O'brien, 1997, Controlled clinical trials.

An approximate likelihood ratio test for a normal mean vector with nonnegative components with application to clinical trials

Nancy L. Geller, Clare Gnecco, N. Geller, 1989 .

Design of Group Sequential Clinical Trials with Multiple Endpoints

Nancy L. Geller, Clare Gnecco, N. Geller, 1989 .

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.

B. Hoogwerf, C. White, M. Domanski, 1999, Diabetes.

Sensitivity analysis using an imputation method for missing binary data in clinical trials

Michael A. Proschan, Nancy L. Geller, Sally Hunsberger, 2001 .

Stochastic curtailing and conditional power in matched case-control studies.

N. Geller, P. Sorlie, S. Hunsberger, 1994, Statistics in medicine.

Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC.

N L Geller, N. Geller, H. Scher, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

N. Geller, A. Krishnan, P. Hari, 2022, Blood Cancer Journal.

Coronary Artery Calcification (CAC) and Post‐Trial Cardiovascular Events and Mortality Within the Women's Health Initiative (WHI) Estrogen‐Alone Trial

Jennifer G. Robinson, J. Manson, A. LaCroix, 2017, Journal of the American Heart Association.

Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

E. Lonn, J. McMurray, S. Pocock, 2012, European heart journal.

Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials

C. Kooperberg, N. Geller, R. Prentice, 2007, Clinical trials.

The effect of a 7‐day delay in chemotherapy cycles on complete response and event‐free survival in good‐risk disseminated germ cell tumor patients

N. Geller, R. Motzer, G. Bosl, 1990, Cancer.

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma

N. Geller, A. Krishnan, P. Hari, 2022, American journal of hematology.

Introduction to the Special Issue: Genome-Wide Association Studies

J. Marchini, N. Geller, G. Zheng, 2009, 1010.4621.

Change in Physical Activity and Sitting Time After Myocardial Infarction and Mortality Among Postmenopausal Women in the Women's Health Initiative‐Observational Study

Andrea K. Chomistek, J. Manson, A. LaCroix, 2017, Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.

Relation between clinical, angiographic and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the Asymptomatic Cardiac Ischemia Pilot study. ACIP Study Group.

N. Geller, P. Stone, G. Knatterud, 1997, Journal of the American College of Cardiology.

A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors

N. Geller, J. Auman, H. Scher, 1989 .

Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer?

O. Dalesio, N. Geller, M. Parmar, 1990, Seminars in oncology.

Joint analysis of case-parents trio and unrelated case-control designs in large scale association studies

Xin Tian, Gang Zheng, Jungnam Joo, 2007, BMC proceedings.

NHLBI clinical trials workshop: an executive summary

Colin O. Wu, D. DeMets, N. Geller, 2012, Statistics in medicine.

Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial

N. Geller, Y. Rosenberg, S. Kimmel, 2010, Clinical trials.

MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.

N. Geller, A. Krishnan, P. Hari, 2021 .

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes.

B. Hoogwerf, C. White, M. Domanski, 2003, American heart journal.

Robust genome-wide scans with genetic model selection using case-control design ∗

Colin O. Wu, N. Geller, J. Joo, 2009 .

Interim Analyses in Randomized Clinical Trials

S. Pocock, N. Geller, 1986 .

Issues in the analysis of clinical trials for opiate dependence.

N. Geller, D. Follmann, M. Wu, 1992, NIDA research monograph.

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

N. Geller, N. Bander, H. Scher, 1988, The Journal of urology.

CARDIOTHORACIC SURGICAL EDUCATION AND

N. Geller, E. Blackstone, M. Russo, 2011 .

Pancreaticoduodenectomy: A 40‐Year Experience

N. Geller, P. Dineen, Shires Gt, 1982 .

Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer.

R. Elashoff, R. Elashoff, M. Gail, 1988, Journal of the National Cancer Institute.

Implementing family-based behavioral treatment in the pediatric primary care setting: Design of the PLAN study.

L. Epstein, N. Geller, K. Schechtman, 2021, Contemporary clinical trials.

Genotype-guided dosing of vitamin K antagonists.

N. Geller, S. Kimmel, B. French, 2014, The New England journal of medicine.

Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function.

S. Solomon, M. Rice, K. Jablonski, 2008, The American journal of cardiology.

Robust ranks of true associations in genome-wide case-control association studies

N. Geller, J. Joo, G. Zheng, 2015 .

A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers

N. Geller, J. Tisdale, R. Childs, 2011, British journal of haematology.

When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches

J. McMurray, S. Pocock, N. Geller, 2012, Circulation. Heart failure.

Evaluating treatment effects in group sequential multivariate longitudinal studies with covariate adjustment

N. Geller, J. Troendle, Neal O. Jeffries, 2022, Biometrics.

Assessment of risk in metastatic testis carcinoma: impact on treatment.

N. Geller, D. Bajorin, G. Bosl, 1991, Urologia internationalis.

N. Geller, A. Krishnan, P. Hari, 2011, The Lancet. Oncology.

Erratum: A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome (British Journal of Haematology 117 (119-126))

N. Geller, N. Young, J. Maciejewski, 2002 .